Liza Villaruz, MD, UPMC Hillman Cancer Center, Pittsburgh, PA, discusses the effects of approving atezolizumab, an anti-PD-L1 monoclonal antibody, in resected non-small cell lung cancer (NSCLC). Atezolizumab has increased the efficacy of surgical resection by improving patient outcomes receiving surgery, and in the IMpower010 trial (NCT02486718), patients with tumors expressing PD-L1 on more than 50% of tumor cells had the most benefit. This interview took place at the 2022 Targeted Therapies of Lung Cancer Meeting (TTLC 2022).
Samreen Ahmed, FRCP, MD, University Hospitals of Leicester, Leicester, UK, provides an overview of the latest developments in adjuvant and neoadjuvant therapies for lung cancer. Osimertinib is a promising therapy for patients with EFGR-mutated lung cancer post-surgery, and adjuvant atezolizumab has demonstrated efficacy in the perioperative setting, making surgery worthwhile for patients. Neoadjuvant therapy is an additional area of interest, where certain groups of patients will benefit from pre-operative treatment. This interview took place at the 20th Annual British Thoracic Oncology Group (BTOG) Conference 2022.
Martin Hutchings, MD, PhD, Copenhagen University Hospital, Copenhagen, Denmark, provides an overview of current developments in the field of immunotherapy in lymphoma. A lot of progress has been made in monoclonal antibodies, bispecific antibodies, as well as chimeric antigen receptor (CAR) T-cell therapies. Dr Hutchings additionally comments on looking forward to the next generation of immunotherapies, such as anti-CD20 IgM antibodies. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
Matthew Davids, MD, Dana-Farber Cancer Institute, Boston, MA, describes the ongoing Phase II ReVenG trial (NCT04895436) of venetoclax and obinutuzumab in pretreated patients with chronic lymphocytic leukemia (CLL). Patients will have been previously treated with venetoclax and obinutuzumab but have relapsed. Additional venetoclax and obinutuzumab will be administered for a year in patients with at least two years of remission, and venetoclax will be administered for two years in patients with one to two years of remission. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
Nathan Fowler, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, shares an overview of the phase III RELEVANCE trial (NCT01650701) of rituximab and lenalidomide (R2) versus rituximab-chemotherapy followed by rituximab maintenance in patients with high tumor burden, untreated follicular lymphoma (FL). Six years after initial treatment, both treatment arms demonstrated similar efficacy and survival, highlighting R2 as a viable chemotherapy-free treatment option. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
Nina Shah, MD, University of California, San Francisco, CA, provides her insights on the future of multiple myeloma treatment. Multiple advancements have been made in recent years, especially with the development of immunotherapies. In addition to existing monoclonal antibodies such as daratumumab and isatuximab, chimeric antigen receptor (CAR) T-cell therapies including idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel) represent alternative therapies for patients with relapsed/refractory multiple myeloma. Dr Shah additionally highlights the development of bispecific T-cell engagers (BiTEs), as well moving immunotherapies into the frontline setting. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
Ryan Lynch, MD, Seattle Cancer Care Alliance, University of Washington, Seattle, WA, describes current treatment options for patients with relapsed/refractory Hodgkin lymphoma who have progressed or are ineligible for transplant. Whilst PD-L1 inhibitors such as pembrolizumab and nivolumab have shown to efficacious in patients, producing durable responses remains a barrier. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
Nirav N. Shah, MD, Medical College of Wisconsin, Milwaukee, WI, discusses data from the single-arm Phase II trial (NCT03436862) of nivolumab, an anti-PD-1 monoclonal antibody, as maintenance therapy in patients with Hodgkin lymphoma who have undergone autologous stem cell transplant. Maintenance brentuximab is currently the standard of care and 37 patients were enrolled in the trial to receive nivolumab. Whilst some patients discontinued treatment due to adverse events, progression-free survival was 92.1% and overall survival was 100% after a 9 month follow-up. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.